patricia peppin and roxanne mykitiuk abstract Achieving gender equity in clinical trials requires that women be included in sufficient numbers to carry out analysis, that sub-sample analyses be performed, and that results be communicated in such a way as to expand medical knowledge, inform policy decisions, and educate patients. In this article, we examine the extent to which Canada promotes gender equity through its laws and guidelines, viewed within the context of its drug safety system and its research ethics board structure. We analyze the structuring of information by the pharmaceutical industry and consider the impact of its promotional activities on the state of gender knowledge and health. In the final section, we propose ways to improve the structuring of health information to promote gender equity.
1998.). A number of considerations inform the need for sex and gender inclusion in the clinical trial process. Most importantly, unless a drug is tested on the entire population that will use it after the drug is on the market, we cannot be satisfied that health is adequately protected and that safety is assured. A study of trials and meta-analyses of drug therapies for myocardial infarction published in five leading medical journals between 1992 and 1996 reveal that women were poorly represented (mean: 24 percent), and that just under a third (32 percent) of forty-two reviewed reports provided results based on gender, and even fewer (12 percent) discussed the differences between men and women .
1 Cardiovascular disease is the leading cause of death of women in Canada and globally.
Analysis of the data for individual subgroups is essential to increasing our knowledge of the effects of a drug. A study of the clinical trials of Vioxx found that more women than men had been included (74 percent were women), but that 80 percent of the trials included no description of the drug's efficacy by sex. Only one trial reported adverse effects data by sex (Ruiz Cantero and Pardo 2006) . This study also notes that in the Spanish trials of Vioxx, 78 percent of the reported side effects of Vioxx were found in women (Cascales, Ruiz Cantero, and Pardo 2003; cited in Ruiz Cantero and Pardo 2006) . Additional support for gender inclusion is found in the clear evidence of sex-based differences in pharmacokinetics and pharmacological effect (pharmacodynamics) (United States Food and Drug Administration [FDA] 1993; United States General Accounting Office 2001b; Peppin 2003) . These results have implications for dosage, as well as the impact of the drug. For example, one post-market study on paroxetine (Paxil/Seroxat) notes "the complete lack of coherent science-based advice on dosage . . . [which] is essential for the safe and effective use of most drugs, but is available for few" (Medawar and Herxheimer 2003/04, 17) .
The need for women's health research has been amply demonstrated through the Women's Health Initiative (WHI), the first longitudinal study of women's health. Starting in 1991, the WHI performed a fifteen-year program of research through clinical trials and an observational study on leading causes of death and disability among postmenopausal women: cardiovascular disease, cancer, and osteoporosis (Women's Health Initiative 2008) . Their clinical trial of hormone replacement therapy challenged conclusions about its benefits and risks and led significant numbers of women to stop the therapy (Rossouw et al. 2002) . Similarly, its study on long-term aspirin use revealed a different impact on heart health between men and women (Mosca et al. 2007 (Mosca et al. , 1231 . empowered to make their own decisions about participation in trials. Also, some trials should take place during pregnancy. Finally, women should not be pressured to participate by the drug industry or physicians, or be made to undergo trials as a means of obtaining otherwise inaccessible care.
Canada has taken a variety of steps to establish standards and organizations to implement its international commitments in the area of women's health. This institutional framework provides the context for a discussion of gender inclusion in research and clinical trials, in particular, and gender equity in health, more broadly. Canada ratified the Convention on the Elimination of All Forms of Discrimination Against Women, article 12, which requires the elimination of discrimination in the field of health and health care, with specific reference to pregnancy services. In 1993, the Canadian government established the Bureau of Women's Health within Health Canada (now referred to as the Bureau of Women's Health and Gender Analysis). The Bureau's mission is to promote equitable health outcomes for women and men and for boys and girls. In 1999, the Bureau published the Women's Health Strategy, which focuses specifically on genderbased analysis, access, and accountability (Health Canada 1999) . 3 In 2000, Canada reiterated its 1995 commitment to the Beijing Declaration at the United Nations and published Health Canada's Gender-Based Analysis Policy (GBA) Policy, which provides an analytic framework within which to assess how government policies, programs, and legislation contribute to gender equality and to more equitable health outcomes (Health Canada 2000) . The Bureau of Women's Health and Gender Analysis describes GBA as using sex and gender to perceive social differences and contexts and to identify how these conditions affect health status and interactions with the health care system (Health Canada 2000) .
As an example, they discuss the clinical trials policy, stating that applying GBA reveals gender bias and raises questions about the scientific validity of studies, resulting in the policy now requiring inclusion of both sexes unless the drug is intended for use in only one sex. The GBA Policy recognizes that a gender perspective is essential to health policy and notes that full integration of gender analysis into planning and operations is required (Health Canada 2000, 6) . The Women's Health Strategy provides the framework for integrating gender-based analysis into programs and policies. The Strategy outlines sixty-four key activities to meet its goals. One activity consists of monitoring the implementation of the inclusion guideline for women in clinical trials. Hankivsky, in her review of Canada's progress on women's health since the Beijing Declaration for the CWHN, concludes that progress was made in the previous ten years, but that "much more work needs to be done to realize the federal government's commitments to Beijing and Beijing+5, among other international obligations" (Hankivsky 2006) . Hankivsky points to six specific problems, among them the lack of a formal mechanism to ensure gender-based analysis in health research, the underrepresentation of women in health and science careers, gender bias in research methods and priorities, and the government's failure to regulate health matters in areas where it has the authority to do so, as it does with drug advertising. In addition, she notes that although the Women's Health Strategy had taken note of the need to be sensitive to diversity, it needs to take full account of the inequities experienced by women who are poor, disabled, aboriginal, or elderly (Hankivsky 2006, 3) .
Drug approval process
The legislation governing drug approval is the Food and Drugs Act, a federal statute (Food and Drugs Act, R.S.C. 1985, C. F-27) . The Act and the Food and Drug Regulations are silent on gender equity (Food and Drug Regulations, C.R.C., c. 870). 4 In 1997, Health Canada issued a guideline on inclusion to apply to all clinical trials, Inclusion of Women in Clinical Trials (Health Canada, Therapeutic Products Directorate Guidelines 1997). The guideline asserts that, " [d] rugs should be studied prior to approval in subjects representing the full range of patients likely to receive the drug once it is marketed." The guideline also states that, "patients of both sexes should be included in the same trials in numbers adequate to allow detection of clinically significant sex-related differences in drug response " and further, that "[a] nalyses to detect the influence of sex should be carried out both for individual studies and in the overall integrated analysis of efficacy and safety."
The stated intent of the guideline is to "encourage the inclusion of women, especially women of child-bearing potential, at the earliest stages of drug development" so that sex-related differences can be identified early and taken into account in Phase III safety and efficacy trials, and to ensure that data will be available to inform physicians and patients about sex-related drug qualities. This point is significant because it is at the early stage of research that the pharma-cokinetics and pharmacological effects are identified. As the guideline notes, these differences might occur in dosage responses, maximum size of effect, or adverse-effect risk. The guideline states that exclusion from early trials out of concern for fetal toxicity is not necessary because women can take adequate precautions against becoming pregnant and exposing a fetus to potential danger. 5 According to the guideline, the decision of whether to enroll pregnant or lactating women in a particular trial must be individualized. Risk should be assessed by patients, their doctors, the manufacturer, and REBs, with oversight by the Therapeutic Products Directorate.
The guideline states the principle of inclusion in a forthright manner and develops the rationale for it. Because the guideline lacks the legal force of a regulation or statute, however, it is comparatively weak. In addition, its reasoning is undermined by its own wording, which suggests a lack of willingness to enforce the guideline, as it is designed to "encourage" and "promote" inclusion. The Minister of Health may reject an application to market a drug on the basis that it fails to meet the requirements of the Food and Drug Regulations or that the application does not contain sufficient information for the minister to assess the safety of the drug or of the clinical trial (Food and Drug Regulations, C.R.C., c. 870, s. C.05.006(b)). 6 This provision applies to those drugs not yet licensed for marketing and to those approved drugs that are being assessed for new uses, formulations, and combinations. Because the inclusion guideline lacks the status of a regulation, it cannot be used directly to reject an application for failure to meet a regulation. Even though it is arguable that a lack of representation and analysis could provide the basis for ministerial rejection on the grounds of inadequate information to assess the safety and efficacy of the drug or the clinical trial, only the regulation for the inclusion principle would provide a clear and unequivocal basis for such a rejection.
Reviewers of the safety and efficacy of new drug submissions must follow a standard operating procedure, which normally requires gender-based analysis as an evaluation method in a number of instances (Health Canada 2006b). Applying the inclusion guidelines at this stage, reviewers consider how the clinical trial population represents the population to whom the drug will be marketed. Where a drug is to be used by women, it would be strongly recommended that it be tested on women. A drug tested only on men, for example, might be allowed to be marketed only to men . 7 Gender also might be considered for safety reasons if a drug is under consideration for a new indication or if a drug under a notice of compliance with conditions is to go through post-market testing. However, in paragraph 4, the procedure provides that " [d] eviations from this procedure may be acceptable, provided the deviations and their justification are documented in the assessment report." Further, the instructions are said to be "a guide for reviewers, but the inclusion or exclusion of information under a section is left to the scientific judgement and discretion of the reviewer"(Health Canada 2006b). Because the review is carried out during the safety and efficacy phase, its potential to enforce a gender review policy is heightened. Under the current legislation, the government has the most power to effect changes during the approval process. The minister is authorized under the Regulations to withhold approval for failure to meet standards; however, after the drug has been approved for marketing, the The International Conference on Harmonisation (ICH) brought together six parties (the governments and pharmaceutical organizations from Japan, the European Union, and the United States) and three observers (Canada, the World Health Organization, and the European Free Trade Association), with a view to harmonizing drug approval processes among countries that choose to incorporate ICH practices into their governing legislation. As Health Canada states on its Web site, Canada has adopted and integrated the good clinical practice principles from the ICH Good Clinical Practice (ICH GCP) guidelines into its 2001 regulations, though they do not have the force of law (Food and Drug Regulations, C.R.C., c. 870, s. C.05.010; Health Canada 2004). 8 Relying on the ICH GCP guideline is problematic to some extent because of the absence of a national regulatory scheme to fill in gaps and the absence of a process to ensure respect for the guideline (Glass and Lemmens 2002, 477) . The 2001 Canadian regulations contain no explicit reference to gender equity. The regulatory impact statement analysis lists ICH guidelines that were to be adopted in Canada (S.O.R./2001-203) . These include Guideline E8 (General Consideration of Clinical Trials) stating the principle that the study population should represent the target population, as in the Canadian inclusion guideline-and requiring pharmacokinetic information for women in Phase I along with certain dose-response information to support drug registration. Further, guidelines E3 and M4E require sex-based identification of the patient population, analysis, and critical assessment of the data by sex. 9 The impact of these policies is softened, however, by opting out statements such as "if the size of the study permits" (Ruiz Cantero and Pardo 2006, 911-12) . As another example, the E6 (R1) Good Clinical Practice guideline currently states at 7.3.6, a provision relating to effects in humans, that "[a] summary of information on the pharmacokinetics of the investigational product(s) should be presented, including the following, if available . . . [p]opulation subgroups (e.g., gender, age . . .)." Once again, the impact of this recommendation is limited by the words "should be presented" and "if available."
In March 2007, the Bureau of Women's Health and Gender Analysis and the Policy Coordination Division of Health Canada convened a day-long conference entitled "Context Matters: A Health Canada Symposium on Gender, Diversity and Clinical Trials." The meeting brought together officials from both the Health Policy and Health Products and Food branches of Health Canada, as well as a number of speakers to consider issues of equity in clinical trials with an emphasis on achieving greater diversity on the basis of gender, ethnicity (including aboriginal populations), and age (including children and the elderly). The conference organizers used the day-long symposium as an opportunity to educate Health Canada officials about the importance of ensuring that gender and diversity considerations are included in the ongoing legislative, regulatory, and policy review. Numerous questions on gender and health were addressed. One speaker, Yvonne Lefebrve, after reviewing the history of the representation of women in clinical trials, concluded by suggesting that the outstanding issues are: monitoring and evaluating the appropriate representation of women in clinical trials and determining whether there is compliance with current standards/regulations, the sex-based disaggregation of data, the need for policies regarding equity and conducting international clinical trials, the inclusion of pregnant women, and the representation of diverse groups of women.
Tri-Council Policy Statement: Ethical conduct for research involving humans
The Tri-Council Policy Statement [TCPS] was adopted following extensive negotiations among the three federally-funded granting councils, to create a common standard for funded research, regardless of discipline. The composition of research ethics boards [REBs] and their mandate to review and approve biomedical research involving humans and to conduct periodic reviews is set out in the Food and Drug Regulations (C.R.C. c. 870, s. C.05.001). The structure and mandate of REBs also are specified in the TCPS, though in somewhat different terms. Clinical trials must be approved by REBs as part of the drug approval process of the regulations under the Food and Drugs Act (Food and Drug Regulations, C.R.C. c. 870, s. C.05.006.(1)(c).). Although the Therapeutic Products Directorate has indicated that all clinical trials are to adhere to the TCPS, a question may be raised about whether this is enforceable (Lemmens and Miller 2003) . As Michael Hadskis has commented, " [d] etermining when a particular activity is captured by the TCPS is not always a straightforward matter" (Hadskis 2007, 262) . The TCPS applies to any research, defined as systematic inquiry to prove facts, principles, or generalizable knowledge that is directly or indirectly funded by the granting councils. Also, following the requirements of the TCPS may be a term of private agreements among institutions or be a requirement of regulatory bodies. Peer-reviewed journals and courts also may promote compliance with the policy statement (Hadskis 2007, 263-64) . The TCPS does not apply in a general manner outside of these contexts. The TCPS is enforced mainly through the denial of funding to proposed research. Rarely, an institution conducting approved and funded research that turns out to not to conform to TCPS requirements may be made to return funding.
The TCPS contains one statement dealing primarily with gender equity: that "[w]omen shall not automatically be excluded from research solely on the basis of sex or reproductive capacity" (TCPS, Article 5.2). In addition, where research is not specific to a group, Article 5.1(a) prohibits researchers from excluding subjects at the recruitment or research stage based on such attributes as culture, race, disability, sex, and so on. These provisions can only be described as weak and ineffectual (McDonald 2001) . By prohibiting only the most egregious exclusions-automatic exclusion solely on sex or reproductive grounds-they permit even non-arbitrary sex-based exclusion.
10 Similarly, exclusion is permitted when a "valid reason" is offered. The provisions contain no requirement that samples contain sufficient numbers for sub-sample analysis to be performed or that such sub-sample analysis be done. An earlier version of these provisions contained stronger language that was "gutted" by the councils (McDonald 2001, 9; citing Baylis, Downie, and Sherwin 1999) . Françoise Baylis, Jocelyn Downie, and Susan Sherwin have described their reaction to the process: "To our surprise and dismay, the first official draft Code of Conduct for Research Involving Human Subjects reduced all of the above proposals to a single prescriptive clause that clearly sought to mask the gendered nature of the problem of exclusion and underrepresentation . . ." (Baylis, Downie, and Sherwin 1999, 253) . REB review plays a central role in protecting patient safety in the Canadian system. The Law Commission of Canada's review of REB governance commented on the excessive and virtually total reliance on REBs to provide assurance of ethical compliance (McDonald 2000) . No formal qualitative review or accreditation process for REBs exists at this time. Health Canada noted this deficiency at the time the 2001 Food and Drug Regulations were put into place and justified not placing more responsibility on REBs than they already had (S.O.R./2001-203). Currently, the National Council on the Ethics of Human Research provides organizational oversight and has supported the implementation of a voluntary accreditation and certification system (Lemmens 2005, 42) .
11
Trudo Lemmens has argued in favor of federal oversight of REBs on the ground that REBs have a public mandate to protect research subjects and the public (Lemmens 2005, 42-43) . The variations in the legal force of the multiple laws, international documents, and guidelines, along with the differences in law applying within provincial and territorial jurisdictions, add to the complexity of the task of evaluating proposed research. The increasing number of multi-site clinical trials and the specialized nature of research create other demands on local REBs. Kathleen Cranley Glass has described the structure in these terms: "[t]he current system of research governance is fragmented and decentralized, without a consistent, accountable, and transparent system of ethics review. We have yet to establish a comprehensive, uniform set of standards or structure for review that would apply to all research involving humans. There are no viable systems of education, accreditation, or monitoring" (Glass 2006, 44) .
One significant drawback of the REB system in Canada is the lack of monitoring of clinical trials and research (Hadskis 2007, 283-84) . Although monitoring clinical trials is part of the REB mandate, 12 many institutions provide insufficient support to perform oversight after the protocol has been approved (McDonald 2001, 12 
Drug safety
The problems in the area of REB review are compounded by the known deficiencies in the system of drug approval and oversight. Health Canada has reviewed the drug approval process and incorporated many of its findings into two documents, Blueprint for Renewal (Blueprint) (Health Canada 2006a) and the revised version following consultation, Blueprint for Renewal II (Blueprint II) (Health Canada 2007) . Most recently, the Minister of Health has introduced a bill that if passed into law, will notably change Canada's drug approval process. 13 A brief consideration of issues facing the drug approval and oversight system in the United States is helpful. In 2006, the United States Government Accountability Office (GAO), the investigative arm of Congress, identified serious problems in the FDA oversight of safety after the product reaches the market (United States Government Accountability Office 2006, 27-29). The 2006 GAO report considers oversight to have been compromised by the lack of tracking of information about safety issues, lack of criteria to determine when safety decisions should be taken and what decisions to take, weak data, and poor decision-making processes. In other words, the most powerful drug regulation agency in the world does not know when or how to make decisions about the safety of drugs. Furthermore, the GAO report notes that in most instances, the FDA lacks legal authority to order a company to perform further tests of safety after its product is on the market.
The Institute of Medicine (IOM) released its much-anticipated report on drug safety soon after, in September 2006 (Institute of Medicine 2006). This report identifies significant impairments in the drug safety system resulting from severe funding constraints that weakened scientific analysis of drug safety, a less than optimal organization culture, and inadequate regulatory authority, most notably with respect to enforcement. The IOM report includes a lengthy list of recommendations directed to a fundamental restructuring of the drug approval process. Among the proposals that would have a significant impact if adopted in Canada are: the limited licensing of new drugs, similar to the progressive licensing framework supported in Blueprint and Blueprint II; labeling requirements to warn consumers that the product is a new drug; an advertising ban for new drugs; mandatory registration of clinical trial results to improve access to drug safety information; and the authority to withdraw the product from the market, impose fines, and issue injunctions for failure to meet obligations to perform safety studies.
Although we must exercise caution in generalizing about drug approval systems, it is clear that any drug safety system that is broken in such fundamental ways lacks the ability to effectively promote public safety and health. The deficiencies in drug safety inevitably have an impact on the ways data on women's health are gathered, assessed, and used. Reforms directed at inclusion and gender equity will be effective only with a broad overhaul of the drug safety system. In Canada, the weak "guarantees" of a guideline and a virtually useless research standard are unlikely to have much impact in a system suffering from its own identified weaknesses.
Canada's recently introduced legislation to amend the Food and Drugs Act, Bill C-51, if enacted, will constitute a significant restructuring of the drug approval process. The bill addresses many of the concerns noted in Blueprint and Blueprint II by developing a progressive licensing framework for drug approval, setting a new standard for risk assessment, and providing means to secure more information about product risks. Under the new framework, the minister is given the power to grant market approval with conditions, to amend those conditions following notice and a hearing, to suspend or revoke a clinical trial authorization in particular circumstances, and to grant licenses for limited uses of drugs. The new standard to be met for drug approval is ministerial satisfaction that the benefits provided by the drug outweigh the risks. If adopted, the risk-benefit standard will mark a change from a more precautionary principle that requires standards to be met after technical review. The bill significantly expands the minister's power over regulation and reporting in the post-market period. The minister will have the power to compel the holder of a market authorization or establishment license to compile information, conduct tests or studies, or monitor experience to obtain additional information relating to the effects of the product on health or safety or to report this information to the minister. As well, subject to the regulations, the minister may compel production of information under their control that is considered necessary to administer the bill. Significantly, the bill enables the minister to require any labeling required to prevent injury to health, a reassessment of a therapeutic product within a set time, and public disclosure of information about risks and benefits.
Bill C-51 does not consider directly issues of gender equity or sub-population testing, although those issues may be addressed in the regulations and through the related initiatives being taken by the government. Blueprint highlights the need to emphasize specific populations in research and policy, noting possible differences in responses to drugs and the need to address specific needs (Health Canada 2006a, 22-23) . Even so, the bill has implications for achieving gender equity in clinical trials and drug safety more generally. For one thing, though progressive licensing can be used to ensure drug safety, it also can be used to approve drugs for marketing more quickly. This latter possibility may create tension with the goal of promoting safety. Blueprint II indicated that the government would consider early access mechanisms in its progressive licensing framework to address the particular therapeutic or health needs of specific populations (Health Canada 2007, 26-27) . Earlier availability can mean that a drug is available earlier to a broader and more representative population than would have been possible at that stage under the current system, but without necessarily completing clinical trials on the full range of populations who will use it. Only if post-market testing actually is achieved will this change be successful for the entire population who will be exposed to the drug. With respect to risk management, Women and Health Protection, in its comment on Blueprint, states that an emphasis on "managing risk" would replace the precautionary principle of health protection (Women and Health Protection 2006). Although under the new bill it is the applicant that must establish that this riskbenefit standard is met, the terms will be subject to wide interpretation. Therefore, without some guidance, ministerial decision-making on this issue raises the possibility of the politicization of the drug approval process. Because the drug regulation system operates within the government rather than through an agency at arm's length, the prospect of politicization is real. Finally, with respect to access to therapeutic information or disclosure, the language of the bill is permissive, stating that the minister "may" disclose to the public information about the risks or benefits associated with a therapeutic product. These shortcomings might serve to exacerbate whatever inequalities women experience in the clinical trial and drug safety context.
In contrast to the previously mentioned concerns, increased oversight in the post-market period greatly favors drug safety and efficacy for the broader range of groups that will use the drugs after marketing commences. Significant improvements in the availability and accessibility of information may be achieved through the new powers to be attributed to the minister. Specifically, the minister will be able to acquire information through the creation of a publicly accessible register of information, through the potential disclosure of confidential business information in certain circumstances, and through mandatory reporting of adverse drug reactions (ADRs) by prescribed institutions. The promotional aspects of information distribution are addressed in several changes addressing criteria for fraud or deception and in a change prohibiting advertisement unless authorized by the regulations, although the bill does not address directly the issue of direct-to-consumer advertising. Strengthened powers of administration and enforcement; expanded powers for inspectors; enhanced remedies for offences, including injunctions, more realistic fines and imprisonment, application of offences to directors and other persons who are parties within corporations; and the requirement that sentencing take into ac-count the harm or risk and vulnerability of consumers are all measures likely to enhance health information and safety. However, the impact of the legislation will depend on the regulations and on the will of the minister.
Common law
Although we are unable to explore this issue in detail, it is worth raising the question of whether a tort lawsuit could be successful based on failure to test drugs on women (Flannery and Greenberg 1994) . It can be argued that an action targeting testing inadequacies would provide an important impetus to manufacturers to include women in their studies, countering the fears of litigation that led drug manufacturers to exclude women. Litigation on this basis might help persuade the industry that it is in their interest to include representative samples and to analyze these data. At the same time, one must ask whether testing drugs on women could itself lead to legal liability. Ellen Wright Clayton has suggested it would not, writing, "the risk of incurring liability during the early stages of drug investigation is actually quite small whereas the potential for substantial liability is much greater once a fetotoxic drug enters widespread use" (Clayton 1994, 103) .
Summary
An overview of Canada's position on gender inclusion in clinical trials reveals numerous achievements, but also shortcomings, which leave ample room for further development. Women's activism and international developments at the United Nations and in the United States have caused the Canadian government to address the issue of how to include women in clinical trials so as to come closer to achieving gender equity in health. The government and affiliated groups have produced policy documents and guidelines. Though perhaps commendable, these guidelines lack the force of law and do not even attempt to require conduct or check to see whether goals have been met. These limitations are exacerbated by the context of drug safety and research ethics boards within which the guidelines operate. The proposed amendments to the federal food and drug legislation extend the promise of increased amounts of health information and greater control by government over the process; however, it is too soon to say whether the move to progressive licensing and a risk-benefit standard will enhance or diminish gender equity. The mechanisms chosen to achieve gender equity remain outside the legislative framework. Finally, whereas the threat of tort litigation might induce drug developers to increase testing of their products on women, this potential course of action remains untested. The next section of this paper looks more closely at the role of the pharmaceutical industry in gender equity in health.
The role of the pharmaceutical industry in gender equity in health
One aspect of gender equity in health is the creation of health information that can serve to improve women's health. For this reason, the way information is constructed and transmitted must be assessed. Information collected about women's reactions to drugs is gathered and filtered through the promotional lens of the pharmaceutical company. The drug industry creates knowledge about their products in a literal and scientific sense through the process of drug research, through the presentation of results to the regulator, through the publication of research results in journals, and through promotional activities (Peppin and Carty 2001) . We have become acutely aware of the dramatic breakdown in the transmission of reliable information through these channels. For example, the cox-2 inhibitor Vioxx was portrayed as a safe and effective means of controlling pain for arthritis patients, and its risks were obscured, as was demonstrated in the report prepared by Representative Henry Waxman for the U.S. House Committee on Government Reform, which provided a rare glimpse of the activities of drug sales representatives (detailers) in their interactions with doctors (Waxman 2005) . Similarly, the antidepressant paroxetine, known as Paxil in North America and Seroxat in Great Britain, was used extensively by adolescents until the BBC program Panorama aired the first in its series of post-market reports on the drug that stimulated an outpouring of evidence of the significant risk of suicide and suicidal ideation (BBC Panorama 2002) .
Sources that appear to be neutral and unbiased, such as government advisory panels and peer-reviewed journals, have had underlying conflicts of interest unmasked (Abramson 2004) . As John Abramson notes in Overdosed America, drug companies can withdraw advertisements from a journal if their requirements are unmet, whereas,"[t]he journals benefit from the publicity gained from publishing large drug company-sponsored studies. This increases the value of their advertising and enables them to sell back to the drug companies reprints of articles, which the drug companies then distribute as marketing tools to doctors" (Abramson 2004, 112-113) . Corruption of the informationdistribution process has occurred through ghost-writing of articles by the industry, industry-funded patient advocacy groups, sponsored conferences, and the selective publication of results (Healy 2003) . As the integrity of the process is jeopardized and health information is skewed, the accuracy of the information applying to women comes into question, and women's health is affected.
Promotion by the pharmaceutical industry creates diseases that can be cured by pills-"selling sickness" or "disease-mongering," in other words (Moynihan, Heath and Henry 2002; Moynihan and Cassels 2005) . Pharmaceutical products create the image of an answer to a "disease" that is aptly described as industry-created, for example, social anxiety disorder or baldness. The dual myths of the need for intervention and of the need for the intervention of a particular drug are created through these images (Peppin and Carty 2001) . Intervention by dealing with underlying problems linked to the social determinants of health has no appeal to the drug industry. Poverty, chronic joblessness, social environments, gender and culture, and a range of other social determinants influence health and access to the health system. Buying into the pharmaceutical model-interventionist, individualistic, technological-leads individuals and governments away from the collective, community-focused, and preventive public health solutions. The social determinants of health approach is linked to gender-based analysis, which helps us to understand how the experiences of women and men are different and similar and how health status, health needs, and health care utilization differ (Lippman 2006; Hankivsky 2006) . Pharmaceutical intervention ignores these links.
These flaws in the construction and transmission of health information have an impact on gender equity. Distortions in data diminish the impact of gender inclusion policies. Gender representation in research is essential to creating knowledge about the impact of drugs on the experiences of women and men. Unless the research is done, and the results accurately conveyed to all who need them, the impact on women's health likely will be unjust.
Data regarding ADRs must be comprehensively examined to determine whether and how gender is a factor. Women were found to experience more ADRs than men. This result is sometimes attributed to women's greater exposure to health professionals and higher level of drug-taking. Bates and Leape reported on studies that indicate that women have a rate of ADR that is 50 percent higher than men, and they considered whether these rates may be affected not only by the greater frequency of medical attention and drugs but also by the periods of women's lives when pharmacokinetics are affected: menarche, pregnancy and delivery, lactation, and menopause (Bates and Leape 2000, 1225; citing Wilson 1984) . Could this rate also result from a lack of knowledge about the impact of drugs on women or on particular groups of women? Beard and Lee (2006, 10) have noted that, "[i]n general, women appear to be at greater risk of ADRs than men. Female patients appear to have a 1.5-1.7-fold greater risk of developing an ADR" (Beard and Lee 2006, citing Rademaker 2001) . The reasons for this are not entirely clear but include gender-related differences in pharmacokinetic, immunological, and hormonal factors, as well as differences in the pattern of medicine use." Elderly women, who make up the majority of elderly people, take multiple prescriptions, the effects of whose interaction remain largely unstudied. Boxer and Shorr have described the impact in these terms: "[a]dverse drug reactions occur about twice as often in older than younger patients. . . . Risk of an adverse drug reaction increases with greater severity of illness, multiple comorbidities, smaller body size, changes in hepatic and renal metabolism and excretion, and prior drug reactions" (Boxer and Shorr 2004, 421) . Studies demonstrate the lack of inclusion and representation of those who will use drugs, with specific reference to elderly patients. One study notes, "NSAIDs are commonly used in elderly people because of the high prevalence of musculoskeletal disorders, especially in women. However, in the major drug trials evaluating NSAIDs, only 2.1% of patients were 65 years of age or over and less than 0.1% were over 75. In practice, elderly people are among the largest users of drugs and have the highest incidence of serious drug-related side effects" (Rochon, Berger, and Gordon 1998, 1373 ; citing data from Rochon et al. 1993) .
In light of these and similar flaws in gathering health information, we have several recommendations for change in the pharmaceutical industry and in regulatory oversight. First, knowledge about drug reactions must be collected in a broad and systematic manner. The Canadian system, like the American, collects drug information through mandatory reporting by drug companies to government and through voluntary reporting by doctors and hospitals. It is possible for Canadian consumers to report directly online, but the weight given to self-reporting is not indicated. When the BBC program Panorama ran the first of its series of programs on the antidepressant Seroxat, they received 1,374 e-mail messages, as well as letters and 862 Web site communications from viewers who described their own experiences with the drug. An analysis of these results concluded that the picture created by reading the reports provided more complete data, including reports of suicides that had not been reported to the British authorities, and contained the context of the events so that the data could be evaluated and the impact on health more realistically assessed (Medawar et al. 2002) . Another study looks at the printouts of reports from the yellow cards submitted by physicians and other health professionals over twelve years (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) on adverse effects of paroxetine. Comparing the professional reports with the reports from patients in the previous study, the authors observe that patient reports "communicate essential information which professional reporters can never be expected to provide. In this case, patients provided reports that were much richer in their descriptions of behavioural phenomena and feelings than the YC [yellow card] reports and often much better at explaining the nature, significance and consequences of adverse drug effects. Patient reports convert the more technical terms that professionals use into understanding" (Medawar and Herxheimer 2003/04, 15) .
The voluntary reporting system results in significant underreporting of adverse events, at a level estimated at 10 percent of what had been experienced, and even the study of the mandatory yellow card system found a significant degree of underreporting (Medawar and Herxheimer 2003/04, 14-15) .
14 Patient safety is jeopardized when early identification of risks is undermined, particularly in the immediate post-market period when the number of individuals exposed to drugs is significantly increased, and the drug is provided to people on whom the drug was not tested. As women experience more ADRs than men, this risk falls disproportionately on women. Although Canada's proposed legislative changes would require ADR reporting by prescribed classes of institutions prescribed by the regulations, this is only a first step.
Data gathering of adverse effects must become much more efficient, accurate, and contextual to protect public health. Health Canada has suggested several approaches to remedy the current deficiencies, including requiring industry to make a submission prior to approval of their plans for pharmacovigilance in the post-market period; establishing the authority under the regulations to require post-market studies; collaborating to develop head-to-head comparison studies and large observational studies; addressing underreporting; developing active surveillance systems; and increasing the government's capacity to assess safety signals (Health Canada 2006a, 21-22) . Another way to achieve this goal is by paying attention to and recording patient descriptions of adverse reactions. The deficiencies of the adverse effect reporting system in Canada have been on Health Canada's radar for decades, and it is time for these useful suggestions to be assessed and implemented fully.
Next, reliable sources of information that are fully independent of the industry are required to maintain the integrity of the public process and restore confidence in the system. An independent evaluator of information also is required to inquire into such issues as gender inclusion and drug advertising.
Having industry pay to have clinical trial data evaluated in the process of drug approval in the United States has led to speedy trials, but these have been linked to a higher level of drug recalls. Eight out of ten drugs withdrawn by the FDA between 1997 and 2000-a very high rate of withdrawal in itself-had greater health risks for women (United States General Accounting Office 2001a).
Also, doctors and patients must be made fully aware of the populations on whom the drug has been tested and the results (Health Canada 2006a, 13) . 15 Access to data must be submitted during the approval process, and unless it is, doctors and patients will lack information that is vital to decision-making (Women and Health Protection 2006). To give meaningful access, the government must require release of data from companies concerned about revealing trade secrets, as in the proposed legislation (Medawar and Herxheimer 2003/04, 18) . Finally, a strong need exists to monitor the inclusion of representative populations through an independent entity. Such an entity also should review drug advertising to prevent the use of stereotypes and to prevent promotion from undermining disclosure. Advertisements directed to prescribing professionals must be subject to enhanced scrutiny on this basis, supported by regulations. Direct-to-consumer advertising, ostensibly prohibited in Canada, must be prohibited in fact. An independent agency could assist in monitoring the distribution of broadcast, print, and online ads. Several authors have suggested that an independent entity of this sort should review the clinical trials process as a whole (Avorn 2005) .
Conclusion
The Canadian government has indicated its strong support for gender equity through its policy statements, institutional structures, and guidelines. At the same time, it has not translated these aspirations into concrete achievements, either by enacting legislation or through administrative oversight. In considering the ways the pharmaceutical industry presents drug information and in the over-emphasis on research ethics board review as the mechanism for monitoring the ethical aspects of drug trials, it is apparent that there is room for improvement in achieving the aspirations of the inclusion policy. We have pointed to the need for specific reforms in the areas of drug approval and the creation of knowledge about drugs as a means to realize these goals. Gender inclusion has significant health rewards for women. Achieving inclusion requires a commitment to using effective legislative and administrative mechanisms, including those that will enhance safety and the provision of health information, to achieve the benefits of the inclusion commitment.
